February 6, 2014 | Israeli company Tiltan Pharma, which is developing a treatment for pancreatic cancer, has raised $1.5 million. The company will use the proceeds to complete its Phase II clinical trial of its metastatic pancreatic cancer treatment TL-118. Details about the source of the investment were not disclosed.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments